Free Trial
NASDAQ:BEAM

Beam Therapeutics Q2 2024 Earnings Report

Beam Therapeutics logo
$20.75 +0.30 (+1.47%)
Closing price 04:00 PM Eastern
Extended Trading
$20.88 +0.13 (+0.60%)
As of 05:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Beam Therapeutics EPS Results

Actual EPS
-$1.11
Consensus EPS
-$1.13
Beat/Miss
Beat by +$0.02
One Year Ago EPS
-$1.08

Beam Therapeutics Revenue Results

Actual Revenue
$11.80 million
Expected Revenue
$14.18 million
Beat/Miss
Missed by -$2.38 million
YoY Revenue Growth
-41.30%

Beam Therapeutics Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Tuesday, August 6, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Beam Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled on Wednesday, August 6, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Beam Therapeutics Earnings Headlines

I warned you about Nvidia… now look what’s happening
Nvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.
See More Beam Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Beam Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beam Therapeutics and other key companies, straight to your email.

About Beam Therapeutics

Beam Therapeutics (NASDAQ:BEAM), Inc. is a biotechnology company pioneering precision genetic medicines through base editing, a next-generation genome editing approach that enables targeted, permanent correction of single nucleotides in DNA without introducing double-strand breaks. The company leverages proprietary base editing platforms to develop treatments for monogenic diseases, immuno-oncology, and other therapeutic areas where precise DNA modifications can deliver durable benefits. Beam’s core technology builds on research from the Broad Institute and Harvard University, positioning the company at the forefront of the gene editing field.

The company’s research pipeline includes several in vivo and ex vivo programs designed to address rare blood disorders and other genetic diseases. Lead programs focus on conditions such as sickle cell disease and beta-thalassemia, with preclinical and early clinical studies evaluating the safety and efficacy of base editing in hematopoietic stem cells. In addition to hematology, Beam is advancing programs targeting lipid disorders through PCSK9 base editing and exploring novel immuno-oncology approaches by modifying immune cell function to enhance anti-tumor activity.

Beam Therapeutics was founded in 2017 and is headquartered in Cambridge, Massachusetts, with research facilities that support both discovery and early development activities. The company has established collaborations and strategic partnerships with leading pharmaceutical organizations to expand its research capabilities and accelerate the translation of its base editing technology. Beam’s team combines expertise in molecular biology, protein engineering, and translational medicine to drive innovation from bench to bedside.

Leadership at Beam includes co-founder Dr. David R. Liu, whose pioneering work in base editing laid the scientific foundation for the company, alongside an experienced executive team focused on clinical development and commercialization strategy. By integrating cutting-edge science with robust translational pathways, Beam Therapeutics aims to deliver transformative therapies that address genetic diseases with high unmet medical need.

View Beam Therapeutics Profile

More Earnings Resources from MarketBeat